Mil y pico millones de Apus. Lo mismo hay un short squezee en breve...
#28968
Re: Novavax (NVAX): Un Nuevo Comienzo
Pedroperezw
¿Pero los indios se vacunan ahora? ¿Alguien sabe algo?
Creo recordar que desde que dejaron las 2 dosis no han vuelto a hacer pedidos de nadie, desde el SI pararon la producción de todo menos de Nvax. Y de esto hace ya 1 año.
Tengo la impresión de que los indios tampoco se van a vacunar como esto no vaya a más, igual que usa y eu.
#28969
Re: Novavax (NVAX): Un Nuevo Comienzo
Con que solo se vacunen los abuelos y los que tenga patologías ya nos daría unas cifras de cientos de millones personas.
Me gusta el cambio. Me gusta la salida de Stan y desde luego me gusta el nuevo CEO. Me gusta mucho la llegada de John Jacobs a la Presidencia de Novavax, no solo por su experiencia en el sector y porque solo con verle y escucharle un poco se ve que transmite mucha mas confianza, energía, positividad y capacidad resolutiva que Stan, sino también porque creo que su llegada aleja las posibilidades de una OPA en el corto plazo y por lo tanto de una venta de Novavax a precio de saldo. https://www.youtube.com/watch?v=5NlphNavAuE
#28972
Re: Novavax (NVAX): Un Nuevo Comienzo
Pedroperezw
Jajaja millones de Apus...
#28973
Re: Novavax (NVAX): Un Nuevo Comienzo
Pedroperezw
Pues eso es lo que va a pasar en todo el mundo.
#28974
Re: Novavax (NVAX): Un Nuevo Comienzo
Pedroperezw
Me parto: Ya tenemos bonus para el nuevo CEO ($3,000,000) y lo más trinchante es que Stan cobrará por sus servicios de consultoría a la compañía hasta Abril de 2024!!
In connection with his appointment, Mr. Jacobs will be granted an option (the “Inducement Option”) to purchase the number of shares of Common Stock determined by dividing $3,000,000 by the per-share Black-Scholes valuation of a share of the Company's common stock, par value $0.01 per share (“Common Stock”), as of the grant date (rounded to the nearest 10), such option to vest as to one-quarter of the underlying shares on the first anniversary of the grant date, and as to the remaining shares in equal monthly installments for 36 months thereafter, in each case generally subject to Mr. Jacobs’ continued employment with the Company through the applicable vesting date. In connection with his appointment, Mr. Jacobs will also be granted a restricted stock unit award (the “Inducement Restricted Stock Units” and, together with the Inducement Option, the “Initial Grant”) with the number of restricted stock units determined by dividing $3,000,000 by the trailing 30-day average of the closing price per share of Common Stock as of the grant date (rounded to the nearest 10), such restricted stock units to vest as to one-third of the shares underlying the grant on each of the first three anniversaries of the grant date, in each case generally subject to Mr. Jacobs’ continued employment with the Company through the applicable vesting date. The Initial Grant will be granted under, and subject to the terms and conditions of, the 2023 Inducement Plan (as defined below).
Under the terms of the Employment Agreement, if Mr. Jacobs’ employment is terminated by the Company without cause or if Mr. Jacobs terminates his employment with the Company for good reason (as such terms are defined in the Employment Agreement), subject to his execution of a release of claims in favor of the Company, he will be entitled to (i) full accelerated vesting of the Initial Grant, with any then-outstanding Inducement Options remaining exercisable for 90 days following his termination of employment (or, if earlier, until the expiration of the original term of such options) and (ii) a lump sum payment equal to (A) 18 months’ of his then-effective salary plus (B) the cost of 18 months’ of his full COBRA premiums. Mr. Jacobs will also be eligible to receive severance payments and benefits under the Company’s Amended and Restated Change in Control Severance Benefit Plan (the “Change in Control Severance Benefit Plan”) upon a Qualifying Termination (as defined in the Change in Control Severance Benefit Plan and without duplication with respect to any severance benefits he is entitled to under the Employment Agreement).
Pursuant to the Employment Agreement, Mr. Jacobs has agreed to a perpetual confidentiality covenant and an assignment of intellectual property covenant and has agreed not to compete with the Company or solicit certain of the Company’s service providers, customers, and suppliers during Mr. Jacobs’ employment and for a period of 18 months following termination of his employment.
Mr. Jacobs and the Company will enter into an indemnification agreement in substantially similar form as Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2010.
There is no arrangement or understanding between Mr. Jacobs and any other person pursuant to which Mr. Jacobs was appointed as an officer or director of the Company. There are no family relationships between Mr. Jacobs and any director or officer of the Company. Mr. Jacobs has no material direct or indirect interest in a related party transaction that requires disclosure.
In connection with his retirement from employment as President and Chief Executive Officer, the Company and Mr. Erck entered into a consulting agreement (the “Consulting Agreement”) pursuant to which Mr. Erck will provide consulting services to the Company following his retirement until April 30, 2024 (subject to earlier termination, the “consulting period”). The Consulting Agreement provides that Mr. Erck will receive a consulting fee (the “Consulting Fee”) of $50,000 per month in respect of his consulting services for the first six months of the consulting period and $25,000 per month in respect of his consulting services for the remaining nine months of the consulting period. Mr. Erck will continue to be eligible to receive a 2022 annual bonus at the same time that bonuses are paid to the Company’s executive officers. The equity awards previously granted to Mr. Erck will continue to be eligible to vest based on his continued service during the consulting period in accordance with their existing terms, and any stock options and stock appreciation rights that remain outstanding and unexercised as of the last day of the consulting period will remain exercisable until the earlier of (i) the end of the one-year period following the last day of the consulting period and (ii) the stated expiration date of such awards (collectively, the “Equity Treatment”). In the event of a change in control (as defined in the Change in Control Severance Benefit Plan) during the consulting period, Mr. Erck will be entitled to accelerated vesting of 100% of his outstanding equity awards. The Company will also reimburse Mr. Erck for certain attorneys’ fees incurred in the negotiation of the Consulting Agreement.
Under the terms of the Consulting Agreement, if Mr. Erck’s service is terminated by the Company without cause or if Mr. Erck terminates his service with the Company for good reason (as such terms are defined in the Consulting Agreement) prior to the end of the consulting period, the Company will pay Mr. Erck the Consulting Fee through April 30, 2024 and his outstanding awards will remain eligible for the Equity Treatment.
The post-termination period applicable to Mr. Erck’s current non-competition and non-solicitation covenants will commence upon his retirement with the Company.
The foregoing descriptions of the material terms of the Employment Agreement for Mr. Jacobs and the Consulting Agreement for Mr. Erck do not purport to be complete and are qualified in their entirety by reference to the full text of the Employment Agreement and the Consulting Agreement, copies of which will be filed with the SEC as exhibits to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
#28975
Re: Novavax (NVAX): Un Nuevo Comienzo
Pedroperezw
Pues mira aquí lo vuelven a dejar caer (including in connection with a merger or acquisition):
Si la venden o se fusionan no creo que lo hagan a estos precios ridículos, ya la subirán, mínimo a 40$ y en un rago de por lo menos $40-$100.
Trabajar lo que se dice trabajar....hacen muy bien su trabajo sobre todo en lo que respecta a los bonuses. 1 millón de acciones para repartir entre colegas.
Adoption of Inducement Plan
On January 5, 2023, the Board approved the Novavax, Inc. 2023 Inducement Plan (the “2023 Inducement Plan”), the form of Non-Statutory Stock Option Agreement under the 2023 Inducement Plan (the “Form Inducement Option Agreement”) and the form of Restricted Stock Unit Award Agreement under the 2023 Inducement Plan (the “Form Inducement RSU Agreement”). Pursuant to the terms of the 2023 Inducement Plan, the Company may grant non-statutory stock options, stock appreciation rights, restricted stock units, restricted stock and other stock-based awards with respect to up to a total of 1,000,000 shares of Common Stock of the Company as an inducement to individuals being hired, or rehired following a bona fide period of interruption of employment, as an employee of the Company or any of its subsidiaries, including in connection with a merger or acquisition. In accordance with Nasdaq Listing Rule 5635(c)(4), the Company did not seek stockholder approval of the 2023 Inducement Plan. The Form Inducement Option Agreement and the Form Inducement RSU Agreement will be used to evidence awards of stock options or restricted stock units, as applicable, that are granted under the 2023 Inducement Plan.
The foregoing is a brief description of the material terms of the 2023 Inducement Plan, the Form Inducement Option Agreement and the Form Inducement RSU Agreement, and is qualified in its entirety by reference to the full text of the 2023 Inducement Plan, the Form Inducement Option Agreement, and the Form Inducement RSU Agreement filed as Exhibit 10.1, Exhibit 10.2, and Exhibit 10.3, respectively, to this Current Report on Form 8-K.
Y ya tenemos el precio objetivo actualizadito y con esa superación de 1B en cap desde 750 que llegó:
#28979
Re: Novavax (NVAX): Un Nuevo Comienzo
Las autoridades sanitarias españolas, italianas y francesas amplían las recomendaciones para vacuna de Novavax
MADRID, 9 Ene. (EUROPA PRESS) - Novavax ha anunciado que la Comisión de Salud Pública (CSP) de España, el Ministerio de Sanidad de Italia y la Alta Autoridad de Salud (HAS) de Francia han publicado recomendaciones actualizadas para ampliar el uso de 'Nuvaxovid' (NVX-CoV2373) en sus respectivos países.
